From May 13 to 15, the 92nd National Pharmaceutical Fair (PHARMCHINA) was grandly held at the Shanghai National Exhibition and Convention Center. As one of the largest and most influential professional events in China's healthcare and wellness industry, this year's fair brought together nearly 3,000 enterprises from both domestic and international pharmaceutical and health nutrition sectors. Jiudian Pharma's General Manager, Mr. Yang, and Operations Director, Ms. Zhu, led the company's sales management team and key business personnel to the event, showcasing a number of flagship products.

At the exhibition, Jiudian Pharma set up a professional display platform, highlighting its star products across multiple therapeutic areas, including anti-inflammatory and analgesic, cardiovascular and cerebrovascular, anti-infective, digestive and metabolic, and respiratory and anti-allergy treatments. The featured products included Jiudian® Ketoprofen Cataplasms, Jiudian® Daiwenjiu Plaster, Jiudian® Emedastine Fumarate Sustained-Release Capsules, Jiudian® Sumatriptan Succinate Capsules, Jiudian® Ziprasidone Hydrochloride Capsules, Jiudian® Choline Fenofibrate Sustained-Release Capsules, and Jiudian® Lansoprazole Enteric-Coated Capsules. The comprehensive lineup fully demonstrated the company's deep product portfolio and R&D capabilities. The booth attracted a steady stream of visitors, with numerous pharmaceutical partners coming to interact and discuss potential collaborations. Jiudian's staff engaged with prospective clients enthusiastically and professionally, delivering precise product information and conducting in-depth discussions on cooperation opportunities.

Jiudian Pharma has long been committed to independent R&D, consistently advancing its product strategy centered on "high-tech, new products, and patented drugs." This focus has enabled the company to build unique differentiated competitive advantages across multiple therapeutic areas. Particularly in the transdermal drug delivery sector, Jiudian has mastered key green synthesis technologies for various APIs and excipients, positioning its R&D and production capabilities for topical patches at the forefront of the industry. The company has successfully developed a blockbuster single product with annual sales exceeding RMB 1 billion. With the upcoming launch of new products such as cilnidipine tablets and lacidipine tablets, Jiudian's product matrix will be further enriched, and its brand influence and market competitiveness are expected to reach new heights.

The three-day event came to a successful close in Shanghai, a city that seamlessly blends openness and innovation. Jiudian Pharma extends its sincere gratitude to all industry peers who visited its booth for exchanges and guidance, as well as to its long-term partners for their continued support. Just as the Huangpu River surges forward, constantly embracing new currents, Jiudian remains committed to its core philosophy of "Mastery in Medicine, Commitment to Health." With a strategic focus on the transdermal drug delivery sector, the company is accelerating its march toward becoming one of the leading domestic pharmaceutical enterprises. Jiudian looks forward to deepening cooperation and fostering collaborative innovation with more pharmaceutical partners, jointly driving new productive forces in the industry and co-creating a high-quality blueprint for the future of China's pharmaceutical sector.